Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

May 31, 2015

Conditions
Stage IV Gastric Cancer With Metastasis
Interventions
DRUG

Trastuzumab

Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)

DRUG

Capecitabine

Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)

DRUG

Oxaliplatin

Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks

Trial Locations (13)

15006

Hospital Juan Canalejo, A Coruña

15009

Centro Oncológico de Galicia, A Coruña

25198

Hospital Arnau de Vilanova de LLeida, Lleida

27003

Hospital Lucus Augusti de Lugo, Lugo

28009

Hospital Gregorio Marañon, Madrid

28046

Hospital La Paz, Madrid

32005

Hospital de Orense, Ourense

33006

Hospital Universitario Cnetral de Asturias, Oviedo

36001

Hospital Provincial de Pontevedra, Pontevedra

36204

Hospital Xeral Cies, Vigo

36211

Hospital de POVISA, Vigo

39008

Hospital Universitario Marqués de Valdecilla, Santander

48013

Hospital de Basurto, Bilbao

All Listed Sponsors
lead

Fundación para el Progreso de la Oncología en Cantabria

OTHER

NCT01503983 - Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive | Biotech Hunter | Biotech Hunter